 | • レポートコード：MRC2-11QY01832 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は虚血性心疾患（IHD）薬のグローバル市場について調査・分析したレポートです。種類別（抗異脂肪血症薬、カルシウムチャネル遮断薬、ベータ遮断薬、ACE阻害薬、ARB、血管拡張薬、抗血栓薬）市場規模、用途別（安定狭心症、不安定狭心症、プリンツメタル狭心症、STEMI、NSTEMI）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別虚血性心疾患（IHD）薬の競争状況、市場シェア ・世界の虚血性心疾患（IHD）薬市場：種類別市場規模 2015年-2020年（抗異脂肪血症薬、カルシウムチャネル遮断薬、ベータ遮断薬、ACE阻害薬、ARB、血管拡張薬、抗血栓薬） ・世界の虚血性心疾患（IHD）薬市場：種類別市場規模予測 2021年-2026年（抗異脂肪血症薬、カルシウムチャネル遮断薬、ベータ遮断薬、ACE阻害薬、ARB、血管拡張薬、抗血栓薬） ・世界の虚血性心疾患（IHD）薬市場：用途別市場規模 2015年-2020年（安定狭心症、不安定狭心症、プリンツメタル狭心症、STEMI、NSTEMI） ・世界の虚血性心疾患（IHD）薬市場：用途別市場規模予測 2021年-2026年（安定狭心症、不安定狭心症、プリンツメタル狭心症、STEMI、NSTEMI） ・北米の虚血性心疾患（IHD）薬市場分析：米国、カナダ ・ヨーロッパの虚血性心疾患（IHD）薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの虚血性心疾患（IHD）薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の虚血性心疾患（IHD）薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの虚血性心疾患（IHD）薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Bayer、Eli Lilly、Novartis、Pfizer、Sanofi ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.
Market Analysis and Insights: Global Ischemic Heart Disease (IHD)Drugs Market
The global Ischemic Heart Disease (IHD)Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Ischemic Heart Disease (IHD)Drugs Scope and Market Size
Ischemic Heart Disease (IHD)Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Ischemic Heart Disease (IHD)Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Ischemic Heart Disease (IHD)Drugs market is segmented into
Anti-dyslipidemic Drugs
Calcium Channel Blockers
Beta-blockers
ACE Inhibitors
ARBs
Vasodilators
Antithrombotic Agents
Segment by Application, the Ischemic Heart Disease (IHD)Drugs market is segmented into
Stable Angina
Unstable Angina
Prinzmetal’s Angina
STEMI
NSTEMI
Regional and Country-level Analysis
The Ischemic Heart Disease (IHD)Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Ischemic Heart Disease (IHD)Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Ischemic Heart Disease (IHD)Drugs Market Share Analysis
Ischemic Heart Disease (IHD)Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Ischemic Heart Disease (IHD)Drugs business, the date to enter into the Ischemic Heart Disease (IHD)Drugs market, Ischemic Heart Disease (IHD)Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca
Bayer
Eli Lilly
Novartis
Pfizer
Sanofi
…
1 Study Coverage
1.1 Ischemic Heart Disease (IHD)Drugs Product Introduction
1.2 Market Segments
1.3 Key Ischemic Heart Disease (IHD)Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Ischemic Heart Disease (IHD)Drugs Market Size Growth Rate by Type
1.4.2 Anti-dyslipidemic Drugs
1.4.3 Calcium Channel Blockers
1.4.4 Beta-blockers
1.4.5 ACE Inhibitors
1.4.6 ARBs
1.4.7 Vasodilators
1.4.8 Antithrombotic Agents
1.5 Market by Application
1.5.1 Global Ischemic Heart Disease (IHD)Drugs Market Size Growth Rate by Application
1.5.2 Stable Angina
1.5.3 Unstable Angina
1.5.4 Prinzmetal’s Angina
1.5.5 STEMI
1.5.6 NSTEMI
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Ischemic Heart Disease (IHD)Drugs Market Size, Estimates and Forecasts
2.1.1 Global Ischemic Heart Disease (IHD)Drugs Revenue 2015-2026
2.1.2 Global Ischemic Heart Disease (IHD)Drugs Sales 2015-2026
2.2 Global Ischemic Heart Disease (IHD)Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Ischemic Heart Disease (IHD)Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Ischemic Heart Disease (IHD)Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Ischemic Heart Disease (IHD)Drugs Competitor Landscape by Players
3.1 Ischemic Heart Disease (IHD)Drugs Sales by Manufacturers
3.1.1 Ischemic Heart Disease (IHD)Drugs Sales by Manufacturers (2015-2020)
3.1.2 Ischemic Heart Disease (IHD)Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Ischemic Heart Disease (IHD)Drugs Revenue by Manufacturers
3.2.1 Ischemic Heart Disease (IHD)Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Ischemic Heart Disease (IHD)Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Ischemic Heart Disease (IHD)Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Ischemic Heart Disease (IHD)Drugs Revenue in 2019
3.2.5 Global Ischemic Heart Disease (IHD)Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Ischemic Heart Disease (IHD)Drugs Price by Manufacturers
3.4 Ischemic Heart Disease (IHD)Drugs Manufacturing Base Distribution, Product Types
3.4.1 Ischemic Heart Disease (IHD)Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Ischemic Heart Disease (IHD)Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Ischemic Heart Disease (IHD)Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Ischemic Heart Disease (IHD)Drugs Market Size by Type (2015-2020)
4.1.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020)
4.1.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Type (2015-2020)
4.1.3 Ischemic Heart Disease (IHD)Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Ischemic Heart Disease (IHD)Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Ischemic Heart Disease (IHD)Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Ischemic Heart Disease (IHD)Drugs Market Size by Application (2015-2020)
5.1.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020)
5.1.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Application (2015-2020)
5.1.3 Ischemic Heart Disease (IHD)Drugs Price by Application (2015-2020)
5.2 Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Ischemic Heart Disease (IHD)Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Ischemic Heart Disease (IHD)Drugs by Country
6.1.1 North America Ischemic Heart Disease (IHD)Drugs Sales by Country
6.1.2 North America Ischemic Heart Disease (IHD)Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Type
6.3 North America Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Ischemic Heart Disease (IHD)Drugs by Country
7.1.1 Europe Ischemic Heart Disease (IHD)Drugs Sales by Country
7.1.2 Europe Ischemic Heart Disease (IHD)Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Type
7.3 Europe Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Ischemic Heart Disease (IHD)Drugs by Region
8.1.1 Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Region
8.1.2 Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Type
8.3 Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Ischemic Heart Disease (IHD)Drugs by Country
9.1.1 Latin America Ischemic Heart Disease (IHD)Drugs Sales by Country
9.1.2 Latin America Ischemic Heart Disease (IHD)Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Type
9.3 Central & South America Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Ischemic Heart Disease (IHD)Drugs by Country
10.1.1 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Country
10.1.2 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Ischemic Heart Disease (IHD)Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Description and Business Overview
11.2.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bayer Ischemic Heart Disease (IHD)Drugs Products Offered
11.2.5 Bayer Related Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Description and Business Overview
11.3.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Eli Lilly Ischemic Heart Disease (IHD)Drugs Products Offered
11.3.5 Eli Lilly Related Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Description and Business Overview
11.4.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novartis Ischemic Heart Disease (IHD)Drugs Products Offered
11.4.5 Novartis Related Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Description and Business Overview
11.5.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Ischemic Heart Disease (IHD)Drugs Products Offered
11.5.5 Pfizer Related Developments
11.6 Sanofi
11.6.1 Sanofi Corporation Information
11.6.2 Sanofi Description and Business Overview
11.6.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Sanofi Ischemic Heart Disease (IHD)Drugs Products Offered
11.6.5 Sanofi Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Ischemic Heart Disease (IHD)Drugs Products Offered
11.1.5 AstraZeneca Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Ischemic Heart Disease (IHD)Drugs Market Estimates and Projections by Region
12.1.1 Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Ischemic Heart Disease (IHD)Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Ischemic Heart Disease (IHD)Drugs Sales Forecast (2021-2026)
12.2.2 North America: Ischemic Heart Disease (IHD)Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Ischemic Heart Disease (IHD)Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Ischemic Heart Disease (IHD)Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Ischemic Heart Disease (IHD)Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Ischemic Heart Disease (IHD)Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Ischemic Heart Disease (IHD)Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Ischemic Heart Disease (IHD)Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Ischemic Heart Disease (IHD)Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Ischemic Heart Disease (IHD)Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Ischemic Heart Disease (IHD)Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Ischemic Heart Disease (IHD)Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Ischemic Heart Disease (IHD)Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Ischemic Heart Disease (IHD)Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Ischemic Heart Disease (IHD)Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Ischemic Heart Disease (IHD)Drugs Market Segments
Table 2. Ranking of Global Top Ischemic Heart Disease (IHD)Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Ischemic Heart Disease (IHD)Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Anti-dyslipidemic Drugs
Table 5. Major Manufacturers of Calcium Channel Blockers
Table 6. Major Manufacturers of Beta-blockers
Table 7. Major Manufacturers of ACE Inhibitors
Table 8. Major Manufacturers of ARBs
Table 9. Major Manufacturers of Vasodilators
Table 10. Major Manufacturers of Antithrombotic Agents
Table 11. Global Ischemic Heart Disease (IHD)Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 12. Global Ischemic Heart Disease (IHD)Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 13. Global Ischemic Heart Disease (IHD)Drugs Sales by Regions 2015-2020 (K Pcs)
Table 14. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Regions (2015-2020)
Table 15. Global Ischemic Heart Disease (IHD)Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 16. Global Ischemic Heart Disease (IHD)Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 17. Global Ischemic Heart Disease (IHD)Drugs Sales Share by Manufacturers (2015-2020)
Table 18. Global Ischemic Heart Disease (IHD)Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Ischemic Heart Disease (IHD)Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Ischemic Heart Disease (IHD)Drugs as of 2019)
Table 20. Ischemic Heart Disease (IHD)Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Ischemic Heart Disease (IHD)Drugs Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Ischemic Heart Disease (IHD)Drugs Price (2015-2020) (USD/Pcs)
Table 23. Ischemic Heart Disease (IHD)Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Ischemic Heart Disease (IHD)Drugs Product Type
Table 25. Date of International Manufacturers Enter into Ischemic Heart Disease (IHD)Drugs Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020) (K Pcs)
Table 28. Global Ischemic Heart Disease (IHD)Drugs Sales Share by Type (2015-2020)
Table 29. Global Ischemic Heart Disease (IHD)Drugs Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Ischemic Heart Disease (IHD)Drugs Revenue Share by Type (2015-2020)
Table 31. Ischemic Heart Disease (IHD)Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 32. Global Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020) (K Pcs)
Table 33. Global Ischemic Heart Disease (IHD)Drugs Sales Share by Application (2015-2020)
Table 34. North America Ischemic Heart Disease (IHD)Drugs Sales by Country (2015-2020) (K Pcs)
Table 35. North America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2015-2020)
Table 36. North America Ischemic Heart Disease (IHD)Drugs Revenue by Country (2015-2020) (US$ Million)
Table 37. North America Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2015-2020)
Table 38. North America Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020) (K Pcs)
Table 39. North America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2015-2020)
Table 40. North America Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020) (K Pcs)
Table 41. North America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application (2015-2020)
Table 42. Europe Ischemic Heart Disease (IHD)Drugs Sales by Country (2015-2020) (K Pcs)
Table 43. Europe Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2015-2020)
Table 44. Europe Ischemic Heart Disease (IHD)Drugs Revenue by Country (2015-2020) (US$ Million)
Table 45. Europe Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2015-2020)
Table 46. Europe Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020) (K Pcs)
Table 47. Europe Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2015-2020)
Table 48. Europe Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020) (K Pcs)
Table 49. Europe Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application (2015-2020)
Table 50. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Region (2015-2020) (K Pcs)
Table 51. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region (2015-2020)
Table 52. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue by Region (2015-2020) (US$ Million)
Table 53. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region (2015-2020)
Table 54. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020) (K Pcs)
Table 55. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2015-2020)
Table 56. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020) (K Pcs)
Table 57. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application (2015-2020)
Table 58. Latin America Ischemic Heart Disease (IHD)Drugs Sales by Country (2015-2020) (K Pcs)
Table 59. Latin America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2015-2020)
Table 60. Latin Americaa Ischemic Heart Disease (IHD)Drugs Revenue by Country (2015-2020) (US$ Million)
Table 61. Latin America Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2015-2020)
Table 62. Latin America Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020) (K Pcs)
Table 63. Latin America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2015-2020)
Table 64. Latin America Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020) (K Pcs)
Table 65. Latin America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application (2015-2020)
Table 66. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Country (2015-2020) (K Pcs)
Table 67. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country (2015-2020)
Table 68. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue by Country (2015-2020) (US$ Million)
Table 69. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country (2015-2020)
Table 70. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Type (2015-2020) (K Pcs)
Table 71. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2015-2020)
Table 72. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales by Application (2015-2020) (K Pcs)
Table 73. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application (2015-2020)
Table 74. AstraZeneca Corporation Information
Table 75. AstraZeneca Description and Major Businesses
Table 76. AstraZeneca Ischemic Heart Disease (IHD)Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 77. AstraZeneca Product
Table 78. AstraZeneca Recent Development
Table 79. Bayer Corporation Information
Table 80. Bayer Description and Major Businesses
Table 81. Bayer Ischemic Heart Disease (IHD)Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 82. Bayer Product
Table 83. Bayer Recent Development
Table 84. Eli Lilly Corporation Information
Table 85. Eli Lilly Description and Major Businesses
Table 86. Eli Lilly Ischemic Heart Disease (IHD)Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 87. Eli Lilly Product
Table 88. Eli Lilly Recent Development
Table 89. Novartis Corporation Information
Table 90. Novartis Description and Major Businesses
Table 91. Novartis Ischemic Heart Disease (IHD)Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 92. Novartis Product
Table 93. Novartis Recent Development
Table 94. Pfizer Corporation Information
Table 95. Pfizer Description and Major Businesses
Table 96. Pfizer Ischemic Heart Disease (IHD)Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 97. Pfizer Product
Table 98. Pfizer Recent Development
Table 99. Sanofi Corporation Information
Table 100. Sanofi Description and Major Businesses
Table 101. Sanofi Ischemic Heart Disease (IHD)Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 102. Sanofi Product
Table 103. Sanofi Recent Development
Table 104. Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 105. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 106. Global Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 107. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 108. North America: Ischemic Heart Disease (IHD)Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 109. North America: Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Europe: Ischemic Heart Disease (IHD)Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 111. Europe: Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 112. Asia Pacific: Ischemic Heart Disease (IHD)Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 113. Asia Pacific: Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 114. Latin America: Ischemic Heart Disease (IHD)Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 115. Latin America: Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 116. Middle East and Africa: Ischemic Heart Disease (IHD)Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 117. Middle East and Africa: Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 118. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 119. Key Challenges
Table 120. Market Risks
Table 121. Main Points Interviewed from Key Ischemic Heart Disease (IHD)Drugs Players
Table 122. Ischemic Heart Disease (IHD)Drugs Customers List
Table 123. Ischemic Heart Disease (IHD)Drugs Distributors List
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Ischemic Heart Disease (IHD)Drugs Product Picture
Figure 2. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Anti-dyslipidemic Drugs Product Picture
Figure 4. Calcium Channel Blockers Product Picture
Figure 5. Beta-blockers Product Picture
Figure 6. ACE Inhibitors Product Picture
Figure 7. ARBs Product Picture
Figure 8. Vasodilators Product Picture
Figure 9. Antithrombotic Agents Product Picture
Figure 10. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application in 2020 & 2026
Figure 11. Stable Angina
Figure 12. Unstable Angina
Figure 13. Prinzmetal's Angina
Figure 14. STEMI
Figure 15. NSTEMI
Figure 16. Ischemic Heart Disease (IHD)Drugs Report Years Considered
Figure 17. Global Ischemic Heart Disease (IHD)Drugs Market Size 2015-2026 (US$ Million)
Figure 18. Global Ischemic Heart Disease (IHD)Drugs Sales 2015-2026 (K Pcs)
Figure 19. Global Ischemic Heart Disease (IHD)Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 20. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region (2015-2020)
Figure 21. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region in 2019
Figure 22. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region (2015-2020)
Figure 23. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region in 2019
Figure 24. Global Ischemic Heart Disease (IHD)Drugs Sales Share by Manufacturer in 2019
Figure 25. The Top 10 and 5 Players Market Share by Ischemic Heart Disease (IHD)Drugs Revenue in 2019
Figure 26. Ischemic Heart Disease (IHD)Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type (2015-2020)
Figure 28. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type in 2019
Figure 29. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Type (2015-2020)
Figure 30. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Type in 2019
Figure 31. Global Ischemic Heart Disease (IHD)Drugs Market Share by Price Range (2015-2020)
Figure 32. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application (2015-2020)
Figure 33. Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Application in 2019
Figure 34. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Application (2015-2020)
Figure 35. Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Application in 2019
Figure 36. North America Ischemic Heart Disease (IHD)Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 37. North America Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 38. North America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country in 2019
Figure 39. North America Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country in 2019
Figure 40. U.S. Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 41. U.S. Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. Canada Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 43. Canada Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 44. North America Ischemic Heart Disease (IHD)Drugs Market Share by Type in 2019
Figure 45. North America Ischemic Heart Disease (IHD)Drugs Market Share by Application in 2019
Figure 46. Europe Ischemic Heart Disease (IHD)Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 47. Europe Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 48. Europe Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country in 2019
Figure 49. Europe Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country in 2019
Figure 50. Germany Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 51. Germany Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. France Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 53. France Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. U.K. Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 55. U.K. Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Italy Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 57. Italy Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Russia Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 59. Russia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 60. Europe Ischemic Heart Disease (IHD)Drugs Market Share by Type in 2019
Figure 61. Europe Ischemic Heart Disease (IHD)Drugs Market Share by Application in 2019
Figure 62. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 63. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 64. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Market Share by Region in 2019
Figure 65. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Region in 2019
Figure 66. China Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 67. China Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. Japan Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 69. Japan Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. South Korea Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 71. South Korea Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. India Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 73. India Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Australia Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 75. Australia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Taiwan Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 77. Taiwan Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Indonesia Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 79. Indonesia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Thailand Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 81. Thailand Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Malaysia Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 83. Malaysia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Philippines Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 85. Philippines Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Vietnam Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 87. Vietnam Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 88. Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Share by Type in 2019
Figure 89. Asia Pacific Ischemic Heart Disease (IHD)Drugs Market Share by Application in 2019
Figure 90. Latin America Ischemic Heart Disease (IHD)Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 91. Latin America Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 92. Latin America Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country in 2019
Figure 93. Latin America Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country in 2019
Figure 94. Mexico Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 95. Mexico Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Brazil Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 97. Brazil Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Argentina Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 99. Argentina Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 100. Latin America Ischemic Heart Disease (IHD)Drugs Market Share by Type in 2019
Figure 101. Latin America Ischemic Heart Disease (IHD)Drugs Market Share by Application in 2019
Figure 102. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 103. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 104. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Market Share by Country in 2019
Figure 105. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Country in 2019
Figure 106. Turkey Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 107. Turkey Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. Saudi Arabia Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 109. Saudi Arabia Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. U.A.E Ischemic Heart Disease (IHD)Drugs Sales Growth Rate (2015-2020) (K Pcs)
Figure 111. U.A.E Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 112. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Share by Type in 2019
Figure 113. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Market Share by Application in 2019
Figure 114. North America Ischemic Heart Disease (IHD)Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 115. North America Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Europe Ischemic Heart Disease (IHD)Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 117. Europe Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Asia Pacific Ischemic Heart Disease (IHD)Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 119. Asia Pacific Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Latin America Ischemic Heart Disease (IHD)Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 121. Latin America Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 123. Middle East and Africa Ischemic Heart Disease (IHD)Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Porter's Five Forces Analysis
Figure 125. Channels of Distribution
Figure 126. Distributors Profiles
Figure 127. Bottom-up and Top-down Approaches for This Report
Figure 128. Data Triangulation
Figure 129. Key Executives Interviewed
虚血性脳卒中治療薬の世界市場（～2026年） Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis. Asia Pacific is anticipated to unfold as the mo…- 炎症性心疾患の世界市場（～2026年） Inflammatory heart disease is mainly caused by various infectious agents which includes viruses, bacteria, fungi and parasites. These infectious agents came into contact with human body via various toxic materials from the environment. Changing lifestyle resulting in higher prevalence of viral and f…
- 先天性心疾患の世界市場（～2026年） A congenital heart disease is a problem in the structure of the heart that is present at birth. The factors driving the growth of the global congenital heart disease market are rising prevalence of congenital heart disease and rise in adoption of minimally invasive procedures. Further, large number …
- リウマチ性心臓病の世界市場（～2026年） Rheumatic heart disease is a complication ofrheumatic fever in which the heart valves are damaged. Increasing environmental pollution resulting in higher prevalence of viral and fungal infection is one of the major factor motivating the growth of this market. In addition, increasing healthcare expen…
- クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…